After confirming HER2 surface expression on both the primary tumor and BM metastasis by immunohistochemistry (IHC; grade 3, intensity score 3; Fig. 1d)14, the child was enrolled on our phase I trial of autologous HER2 CAR T cells in patients with advanced sarcoma. The gene discussed is ERBB2; the disease is neoplasm.